What is Opgen's earnings per share (EPS)?

Opgen (OPGN) reported diluted earnings per share of $2.30 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opgen Financials

OPGN

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Opgen (OPGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OPGN FY2024 2026-04-22

CapForce’s FY2024 profit swing came mainly from a drastic cost reset, while the business still consumed cash.

Between FY2023 and FY2024, revenue added only $1.8M, but SG&A fell by $3.5M and R&D dropped by roughly $4.7M; that is why operating results crossed into the black with just $325K of operating income. The more revealing contrast is that net income reached $12.0M while operating cash flow stayed at -$4.9M, so the headline profit did not come from cash-generating core operations.

The balance-sheet posture improved sharply in FY2024: liabilities fell from $13.4M to $2.5M, equity turned positive at $7.4M, and the current ratio moved from 0.1x to 4.2x. But because financing cash flow was $5.0M, close to the year’s operating cash burn, the liquidity repair looks externally funded rather than earned through recurring operations.

Across FY2020-FY2023, revenue stayed in a narrow $2.6M to $4.3M band while annual operating cash burn remained roughly -$14.3M to -$23.4M. That gap shows a business weighed down by fixed operating overhead, not by heavy reinvestment, because historical capex was modest relative to the cash consumed simply running the company.

Financial Health Signals

Financial Profile 46/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Opgen's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Opgen has an operating margin of 6.3%, meaning the company retains $6 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Growth

100

Opgen's revenue surged 52.0% year-over-year to $5.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Opgen carries a low D/E ratio of 0.34, meaning only $0.34 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.18, Opgen holds $4.18 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.

Returns

Opgen generates a 162.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Altman Z-Score Distress

-39.73

Opgen scores -39.73, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.3M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Weak

2/9

Opgen passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

-0.41x

For every $1 of reported earnings, Opgen generates $-0.41 in operating cash flow (-$4.9M OCF vs $12.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

43.0x

Opgen earns $43.0 in operating income for every $1 of interest expense ($325K vs $8K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.2M

YoY+52.0%

5Y CAGR+8.2%

10Y CAGR+2.3%

Opgen generated $5.2M in revenue in fiscal year 2024. This represents an increase of 52.0% from the prior year.

EBITDA

$499K

Opgen's EBITDA was $499K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

$12.0M

Opgen reported $12.0M in net income in fiscal year 2024.

EPS (Diluted)

$2.30

Opgen earned $2.30 per diluted share (EPS) in fiscal year 2024. This represents an increase of 105.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.3M

YoY+13.8%

5Y CAGR-13.5%

10Y CAGR+5.7%

Opgen held $1.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

10M

Opgen had 10M shares outstanding in fiscal year 2024. This represents an increase of 685.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

6.3%

5Y CAGR+357.0pp

10Y CAGR+141.1pp

Opgen's operating margin was 6.3% in fiscal year 2024, reflecting core business profitability.

Net Margin

230.8%

5Y CAGR+586.5pp

10Y CAGR+368.2pp

Opgen's net profit margin was 230.8% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

162.5%

5Y CAGR+452.4pp

Opgen's ROE was 162.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$49K

YoY-99.0%

5Y CAGR-60.6%

10Y CAGR-36.2%

Opgen invested $49K in research and development in fiscal year 2024. This represents a decrease of 99.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

OPGN Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$5.2M+52.0%	$3.4M+31.1%	$2.6M-39.5%	$4.3M+2.2%	$4.2M+20.5%	$3.5M
Cost of Revenue	N/A	$3.1M-7.1%	$3.3M+44.6%	$2.3M	N/A	N/A
Gross Profit	N/A	$334K+146.9%	-$712K-135.4%	$2.0M	N/A	N/A
R&D Expenses	$49K-99.0%	$4.7M-42.1%	$8.2M-25.1%	$10.9M+9.5%	$10.0M+94.6%	$5.1M
SG&A Expenses	$4.5M-43.8%	$8.1M-9.0%	$8.9M-10.6%	$9.9M+12.9%	$8.8M+40.8%	$6.3M
Operating Income	$325K	N/A	-$34.6M-48.5%	-$23.3M-2.4%	-$22.7M-85.1%	-$12.3M
Interest Expense	$8K-99.6%	$1.8M-43.5%	$3.3M-32.1%	$4.8M+41.2%	$3.4M+1712.5%	$188K
Income Tax	$177K	N/A	N/A	$44K-66.9%	$132K	$0
Net Income	$12.0M	N/A	-$37.3M-7.1%	-$34.8M-32.8%	-$26.2M-110.6%	-$12.4M
EPS (Diluted)	$2.30	$-41.47	$-152.70	$-22.89	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	$4.0M	N/A	N/A	N/A	$28K-83.3%	$168K-84.3%	$1.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$73K-93.7%	$1.2M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$95K+206.9%	-$89K
R&D Expenses	N/A	N/A	N/A	N/A	$488-97.9%	$23K-11.2%	$26K-92.1%	$329K
SG&A Expenses	$702K+18.0%	$595K+15.9%	$513K	N/A	$769K-51.0%	$1.6M-6.9%	$1.7M+40.6%	$1.2M
Operating Income	-$702K-120.6%	$3.4M+750.8%	-$523K	N/A	-$784K+49.3%	-$1.5M+11.3%	-$1.7M	N/A
Interest Expense	$4K+141.3%	$2K-49.9%	$3K	N/A	$3K+200.1%	$1K	$0-100.0%	$140K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$609K-117.3%	$3.5M+960.0%	-$408K	N/A	$8.9M+666.6%	-$1.6M-647.4%	$288K	N/A
EPS (Diluted)	$-0.06-117.6%	$0.34+950.0%	$-0.04	N/A	$1.35	$-1.18-886.7%	$0.15	N/A

OPGN Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$9.9M+424.0%	$1.9M-92.7%	$25.8M-64.0%	$71.7M+44.1%	$49.8M+377.4%	$10.4M
Current Assets	$2.6M+67.7%	$1.6M-85.2%	$10.7M-73.2%	$39.7M+135.3%	$16.9M+153.3%	$6.7M
Cash & Equivalents	$1.3M+13.8%	$1.2M-84.5%	$7.4M-79.4%	$36.1M+170.1%	$13.4M+393.3%	$2.7M
Inventory	N/A	N/A	$3.6M-22.6%	$4.7M+48.5%	$3.2M+570.6%	$473K
Accounts Receivable	$29K-71.7%	$103K-79.9%	$514K-56.1%	$1.2M+79.5%	$653K+15.0%	$568K
Goodwill	N/A	N/A	$0-100.0%	$7.5M-7.1%	$8.0M+1235.6%	$601K
Total Liabilities	$2.5M-81.5%	$13.4M-26.3%	$18.2M-40.1%	$30.4M+6.6%	$28.6M+366.0%	$6.1M
Current Liabilities	$634K-94.4%	$11.4M+7.8%	$10.6M-46.8%	$19.9M+170.2%	$7.4M+49.3%	$4.9M
Long-Term Debt	N/A	N/A	$4.9M-32.4%	$7.2M-63.0%	$19.4M+5782.1%	$329K
Total Equity	$7.4M+163.8%	-$11.6M-252.6%	$7.6M-81.6%	$41.2M+94.5%	$21.2M+393.6%	$4.3M
Retained Earnings	-$293.5M+3.9%	-$305.5M-12.0%	-$272.8M-15.8%	-$235.5M-17.3%	-$200.7M-15.0%	-$174.5M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$12.6M-4.6%	$13.2M+40.6%	$9.4M-4.5%	$9.9M+80.3%	$5.5M+90.6%	$2.9M-0.1%	$2.9M+52.6%	$1.9M
Current Assets	$5.5M-9.7%	$6.1M+173.3%	$2.2M-15.5%	$2.6M-17.7%	$3.2M+461.7%	$573K+7.5%	$533K-66.3%	$1.6M
Cash & Equivalents	$414K-50.2%	$832K-25.3%	$1.1M-15.1%	$1.3M-19.7%	$1.6M+871.5%	$168K-37.2%	$267K-76.8%	$1.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$4.0M+0.1%	$4.0M+11745.8%	$34K+16.5%	$29K+19.9%	$24K-3.9%	$25K-33.1%	$38K-63.3%	$103K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-3.8%	$2.6M+9.0%	$2.4M-4.7%	$2.5M-0.1%	$2.5M-82.9%	$14.5M+6.3%	$13.7M+1.8%	$13.4M
Current Liabilities	$782K-5.4%	$827K+46.8%	$563K-11.1%	$634K+7.5%	$590K-95.3%	$12.6M+7.7%	$11.7M+2.4%	$11.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.2M-4.8%	$10.7M+51.2%	$7.1M-4.4%	$7.4M+147.2%	$3.0M+125.6%	-$11.7M-7.9%	-$10.8M+6.5%	-$11.6M
Retained Earnings	-$291.0M-0.2%	-$290.4M+1.2%	-$293.9M-0.1%	-$293.5M+1.5%	-$297.9M+2.9%	-$306.8M-0.5%	-$305.2M+0.1%	-$305.5M

OPGN Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$4.9M+66.0%	-$14.3M+30.0%	-$20.4M+4.8%	-$21.5M+8.2%	-$23.4M-103.4%	-$11.5M
Capital Expenditures	N/A	$800K+35.5%	$591K-70.2%	$2.0M+1421.7%	$130K+309.6%	$32K
Free Cash Flow	N/A	-$15.1M+28.1%	-$21.0M+10.3%	-$23.5M+0.3%	-$23.5M-103.9%	-$11.5M
Investing Cash Flow	N/A	-$800K-35.5%	-$591K+70.2%	-$2.0M-86.5%	-$1.1M+57.5%	-$2.5M
Financing Cash Flow	$5.0M-39.9%	$8.4M+224.3%	-$6.7M-114.2%	$47.5M+39.2%	$34.1M+180.1%	$12.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$333K+25.5%	-$447K-126.1%	-$198K+14.8%	-$232K+91.8%	-$2.8M-293.4%	-$720K+33.6%	-$1.1M+35.3%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$914
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.7M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$914
Financing Cash Flow	-$84K	N/A	N/A	-$90K-102.1%	$4.3M+592.3%	$621K+210.9%	$200K-90.5%	$2.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OPGN Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	9.8%+37.1pp	-27.3%-74.0pp	46.7%	N/A	N/A
Operating Margin	6.3%	N/A	-1325.8%-785.3pp	-540.5%-1.4pp	-539.1%-188.3pp	-350.8%
Net Margin	230.8%	N/A	-1430.0%-621.7pp	-808.3%-186.4pp	-621.9%-266.2pp	-355.8%
Return on Equity	162.5%	N/A	-492.1%-407.7pp	-84.4%+39.3pp	-123.7%+166.2pp	-289.9%
Return on Assets	121.6%	N/A	-144.4%-95.9pp	-48.6%+4.1pp	-52.7%+66.7pp	-119.4%
Current Ratio	4.18+4.0	0.14-0.9	1.01-1.0	2.00-0.3	2.29+0.9	1.35
Debt-to-Equity	0.34+1.5	-1.16-1.8	0.64+0.5	0.17-0.7	0.91+0.8	0.08
FCF Margin	N/A	-442.3%+364.7pp	-807.0%-262.1pp	-544.9%+13.4pp	-558.2%-228.5pp	-329.8%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	56.5%+64.8pp	-8.3%
Operating Margin	N/A	85.1%	N/A	N/A	N/A	-5526.1%-4488.2pp	-1038.0%	N/A
Net Margin	N/A	87.8%	N/A	N/A	N/A	-5629.8%-5801.1pp	171.3%	N/A
Return on Equity	-6.0%-38.9pp	32.9%+38.7pp	-5.8%	N/A	299.1%	N/A	N/A	N/A
Return on Assets	-4.8%-31.3pp	26.5%+30.8pp	-4.3%	N/A	163.3%+218.2pp	-54.9%-65.0pp	10.0%	N/A
Current Ratio	7.06-0.3	7.39+3.4	3.97-0.2	4.18-1.3	5.46+5.4	0.050.0	0.05-0.1	0.14
Debt-to-Equity	0.240.0	0.24-0.1	0.340.0	0.34-0.5	0.83+2.1	-1.25+0.0	-1.27-0.1	-1.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-156.8%

Similar Companies

Motus Gi Hldgs Inc MOTS

$435K

Thermogenesis Holdings Inc THMO

$5.4M

Micron Solutions MICR

$634

CS Diagnostics CSDX

$15.5M

Pressure Bio PBIO

$4K

Frequently Asked Questions

What is Opgen's annual revenue?

Opgen (OPGN) reported $5.2M in total revenue for fiscal year 2024. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Opgen's revenue growing?

Opgen (OPGN) revenue grew by 52% year-over-year, from $3.4M to $5.2M in fiscal year 2024.

Is Opgen profitable?

Yes, Opgen (OPGN) reported a net income of $12.0M in fiscal year 2024, with a net profit margin of 230.8%.

What is Opgen's EBITDA?

Opgen (OPGN) had EBITDA of $499K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Opgen's operating margin?

Opgen (OPGN) had an operating margin of 6.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Opgen's net profit margin?

Opgen (OPGN) had a net profit margin of 230.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Opgen's return on equity (ROE)?

Opgen (OPGN) has a return on equity of 162.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Opgen's operating cash flow?

Opgen (OPGN) generated -$4.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Opgen's total assets?

Opgen (OPGN) had $9.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Opgen spend on research and development?

Opgen (OPGN) invested $49K in research and development during fiscal year 2024.

How many shares does Opgen have outstanding?

Opgen (OPGN) had 10M shares outstanding as of fiscal year 2024.

What is Opgen's current ratio?

Opgen (OPGN) had a current ratio of 4.18 as of fiscal year 2024, which is generally considered healthy.

What is Opgen's debt-to-equity ratio?

Opgen (OPGN) had a debt-to-equity ratio of 0.34 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Opgen's return on assets (ROA)?

Opgen (OPGN) had a return on assets of 121.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Opgen's cash runway?

Based on fiscal year 2024 data, Opgen (OPGN) had $1.3M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Opgen's Altman Z-Score?

Opgen (OPGN) has an Altman Z-Score of -39.73, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Opgen's Piotroski F-Score?

Opgen (OPGN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Opgen's earnings high quality?

Opgen (OPGN) has an earnings quality ratio of -0.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Opgen cover its interest payments?

Opgen (OPGN) has an interest coverage ratio of 43.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Opgen?

Opgen (OPGN) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.